Companies /Healthcare

Danaher Corp

NYSE: DHR Diagnostics & Research
$215.36
▼ $0.61 (−0.28%) today
Markets open · 1:54pm ET

Q3 2025 Earnings

Reported Oct 20, 2025, 5:39pm ET · SEC source
$1.89
Beat +9.78%
EPS · est. $1.72
$6.1B
Beat +0.92%
Revenue · est. $6.0B
+8.0%
Beating market
DHR vs S&P since report
4 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
0+5%+10%Oct 20Oct 21report 5:39pm ETearnings−0.1%+6.7%
0+5%+10%Oct 20Oct 21earnings−0.1%+6.7%
DHR +6.7%S&P 500 −0.1%
0+4%+8%Oct 20Oct 21report 5:39pm ETearnings−0.3%+6.7%
0+4%+8%Oct 20Oct 21earnings−0.3%+6.7%
DHR +6.7%NASDAQ −0.3%
0+4%+8%Oct 20Oct 28report 5:39pm ETearnings+2.3%+4.8%
0+4%+8%Oct 20Oct 28earnings+2.3%+4.8%
DHR +4.8%S&P 500 +2.3%
0+4%+8%Oct 20Oct 28report 5:39pm ETearnings+3.4%+4.8%
0+4%+8%Oct 20Oct 28earnings+3.4%+4.8%
DHR +4.8%NASDAQ +3.4%
−0.32%
Day of report
+5.94%
Next session
+6.06%
One week
+6.73%
30 days

S&P 500 over the same 30 days: −1.29%.

Did DHR Beat Earnings? Q3 2025 Results

Danaher delivered a strong third quarter for 2025, with both earnings and revenue clearing consensus estimates as the life sciences and diagnostics company demonstrated broadening momentum across its portfolio. Non-GAAP adjusted diluted EPS came in at $1.89, beating the $1.72 consensus by 9.78%, while revenue of $6.05 billion edged past the $6.00 billion estimate and grew 4.4% year-over-year. The standout driver was the Biotechnology segment, which posted 9.0% total sales growth fueled by continued strength in bioprocessing, helping offset a modest 1.0% core revenue decline in Life Sciences. Operating cash flow climbed to $1.66 billion from $1.51 billion a year earlier, reflecting solid execution across the business. Looking ahead, management maintained its full-year adjusted diluted EPS guidance of $7.70 to $7.80, with non-GAAP core revenue expected to grow low-single digits, while fourth-quarter guidance points to Biotechnology core growth of approximately 5% and a roughly 2.5% currency tailwind supporting reported sales.

Key Takeaways
  • Continued momentum in bioprocessing business
  • Better-than-anticipated respiratory revenue at Cepheid
  • DBS-driven execution and productivity gains
  • Favorable currency exchange rates providing 1.5% sales tailwind

“We are encouraged by our third quarter results. DBS-driven execution paired with continued momentum in our bioprocessing business and better-than-anticipated respiratory revenue at Cepheid enabled us to exceed our revenue, earnings and cash flow expectations.”

Danaher CEO, on the earnings call

Forward Guidance & Outlook

For full year 2025, Danaher is maintaining its adjusted diluted net earnings per common share guidance range of $7.70 to $7.80, with non-GAAP core revenue expected to grow low-single digits year-over-year. For Q4 2025, the company expects Biotechnology core sales growth of approximately 5%, Life Sciences to decline low-single digits, and Diagnostics to be flat, resulting in overall low-single digit core sales growth. Currency exchange rates are expected to increase Q4 sales by approximately 2.5%. Q4 assumptions include corporate expense of approximately $85 million, net interest expense of approximately $50 million, and an effective tax rate of approximately 17%.

DHR YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$0$2.0B$4.0B$6.0B$5.8B$6.1BRevenue$3.4B$3.5BGross Profit$958.0M$1.2BOperating Income$818.0M$908.0MNet Income
$0$2.0B$4.0B$6.0BRevenueGross ProfitOperating IncomeNet Income

DHR Revenue by Segment

Diagnostics
Life Sciences
Biotechnology

Figures from SEC filings and company reports. Not investment advice.